COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
Status:
Not yet recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
Similar to the paradigm established in other hematologic malignancies that are considered
curable, the achievement of MRD(-) status is necessary for long term disease control in MM.
The fact that the majority of patients remain MRD (+) after induction therapy and AHCT points
to the opportunity to deploy novel agents with complementary mechanism of action and
favorable toxicity profile to reach and maintain MRD (-) status.
Given its favorable toxicity profile, the convenience of oral administration, and compelling
single agent activity even in heavily pretreated MM, iberdomide is likely amenable to long
term therapy in patients with high-risk of relapse/progression identified by the persistence
of MRD(+). The investigators intend to develop combination(s) of iberdomide with other agents
with complementary mechanism of action in the consolidation setting post AHCT in order to
achieve and sustain MRD (-).